Ignite Creation Date:
2024-05-05 @ 5:25 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00453440
Status:
COMPLETED
Last Update Posted:
2017-09-12
First Post:
2007-03-28
Brief Title:
Prospective Epidemiological Study Of The Prevalence Of HLA-B5701
Sponsor:
ViiV Healthcare
Organization:
ViiV Healthcare
Study Overview
Official Title:
Prospective Epidemiological Study of the Prevalence of HLA-B5701 in HIV-1 Infected UK Patients
Status:
COMPLETED
Status Verified Date:
2017-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study to determine the prevalence of a genetic marker HLA-B5701 in the UK population HLA-B5701 has been strongly associated with the risk of an allergic reaction to a HIV medicine Abacavir The allergic reaction is known as a hypersensitivity reaction
The study is a prospective study inviting HIV-1 positive patients over the age of 18 years to participate Each participant will complete one study visit They will be asked for details of their background including their age sex ethnicity country of origin and parental country of origin
They will be asked to give two samples to test for the presence of the genetic marker HLA-B5701 The two samples are
A cheek swab
A blood sample
In selected centres patients may be asked to provide up to two additional blood samples These samples will be used to help develop and validate new methods of determining HLA-B5701 testing
The study is a prospective study inviting HIV-1 positive patients over the age of 18 years to participate Each participant will complete one study visit They will be asked for details of their background including their age sex ethnicity country of origin and parental country of origin
They will be asked to give two samples to test for the presence of the genetic marker HLA-B5701 The two samples are
A cheek swab
A blood sample
In selected centres patients may be asked to provide up to two additional blood samples These samples will be used to help develop and validate new methods of determining HLA-B5701 testing
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None